5 billion new dosage forms of antihypertensive drugs, this pharmaceutical company will win

Medical Network News, August 27.
Recently, Changzhou Siyao entered the administrative examination and approval stage with the imitation of the 3 types of valsartan oral solution, which is expected to become the first valsartan oral solution product in China
.
Valsartan is a commonly used antihypertensive drug in clinical practice.
In 2020, the total sales of valsartan in Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 5 billion yuan
.
Valsartan belongs to an angiotensin Ⅱ receptor antagonist class of antihypertensive drugs.
It is one of the most widely used antihypertensive drugs in the domestic market
.
The original manufacturer of this product was Novartis, and it was approved for marketing in the United States in July 2001.
It is mainly used for the treatment of mild to moderate essential hypertension
.
According to data from Mi Nei.
com, in 2020, the total sales of valsartan in Chinese urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and the terminal valsartan in Chinese urban physical pharmacies will exceed 5 billion yuan.
The market share of pharmaceuticals is leading among domestic manufacturers
.
Sales of valsartan at the terminal of physical pharmacies in Chinese cities (unit: 10,000 yuan) Source: Mynet.
com.
The terminal competition pattern of physical pharmacies in Chinese cities.
Huahai, Hunan big one thousand Jin Xiangjiang and medicine, and other five companies won the bid
.
Affected by the epidemic and centralized procurement, the terminal sales of valsartan in China's public medical institutions fell by 10.
47% in 2020, while the sales of valsartan in the physical pharmacies of Chinese cities did not fall but rose, and remained at the level of 1 billion yuan
.
Source of application status of valsartan oral solution listing: One-click search on Mynet.
com.
At present, valsartan products that have been marketed in China include tablets, dispersible tablets and capsules.
No company has been approved for the listing of oral liquids. .
Changzhou Siyao and Guangzhou Yipinhong Pharmaceutical successively submitted applications for the imitation of valsartan oral solution for 3 types of listing.
The registration status of Changzhou Siyao's product has been changed to "under review".
A valsartan oral solution product
.
Data source: Meinenet database, NMPA Note: Meinenet China's urban physical pharmacy terminal competition pattern database is an enlarged version of continuous monitoring of all categories covering 293 cities and above cities across the country (excluding county and rural physical pharmacies) Database of physical pharmacies in cities
.
The above sales are calculated based on the average retail price of the product at the terminal
.